Published April 22, 2025 | Version v1
Dataset Open

Data from: Aberrant Striatal Firing Mediates Impulsive Decision-Making in a Mouse Model of Parkinson's Disease

  • 1. ROR icon University of California, San Francisco

Contributors

Description

Parkinson's disease (PD) is characterized by progressive neurodegeneration, which is associated with motor and non-motor symptoms. Dopamine replacement therapy can remediate motor symptoms, but can also cause impulse control disorder (ICD), characterized by pathological gambling, hypersexuality, and/or compulsive shopping. Approximately 14-40% of all medicated PD patients suffer from ICD. Despite the high prevalence of ICD in medicated PD patients, we know little of its mechanisms, and the main therapeutic strategy is reducing or eliminating dopamine agonist medication. Human imaging studies suggest that the input nucleus of the basal ganglia, the striatum, may be a critical site of circuit dysfunction in ICD.

To explore the cellular and circuit mechanisms of ICD, we developed a mouse model in which we administered the dopamine D2/3 agonist pramipexole to parkinsonian and healthy control mice. ICD-like behavior was assessed using a delay discounting task. Delay discounting is a normal cognitive phenomenon, in which the value of a reward decreases according to the time needed to wait for it. Impulsivity is measured as the preference for immediate (small) over delayed (large) rewards. We combined this mouse model with chemogenetics and in vivo optically-identified single-unit recordings to examine how dopamine agonists act on vulnerable striatal circuitry to mediate impulsive decision-making.

We found that in parkinsonian mice, therapeutic doses of dopamine D2/3R or D1R agonists drove more pronounced delay discounting, reminiscent of what has been reported in PD/ICD patients on medication. In contrast, healthy mice did not become more impulsive when given the same dose of dopamine agonist. The clinically relevant dopamine D2/3R agonist pramipexole induced marked bidirectional changes in the firing of striatal direct and indirect pathway neurons in parkinsonian mice. Chronic pramipexole treatment potentiated these changes in striatal physiology and decision-making behavior. Furthermore, chemogenetic excitation of direct pathway striatal neurons or inhibition of indirect pathway neurons induced impulsive decision making in the absence of dopamine agonists. These findings indicate that abnormal striatal activity plays a causal role in mediating ICD-like behaviors. Together, they provide a robust mouse model and insights into ICD pathophysiology.

Files

Data_ICD_A77636OpenField_Raw.zip

Files (37.7 GB)

Name Size Download all
md5:1e154fb5ae37d95e145f083ec3fe05cf
75.9 MB Preview Download
md5:a7f44aa0cddf55a9856a14de6436edf8
35.9 MB Preview Download
md5:f664394131446bc60ffc45c3c79f7f92
10.8 kB Download
md5:1e44d08f5ec0c66b7ccefe78781de696
243.9 kB Download
md5:e48cd0ba4e705c58f6b16809ba123d51
81.9 MB Preview Download
md5:f5d3336d6acbcfcd74ea545b5216ad54
9.2 GB Preview Download
md5:c8600a97a775263b9d928e0f79a0f8a6
137.6 kB Download
md5:beedac9cd80832cd44721fa7cc5aaf1d
10.5 kB Download
md5:a50707dc5299bfe74572707d42f4228f
2.5 GB Preview Download
md5:86d8ad67e6704c57cad806a02bc2da60
4.3 GB Preview Download
md5:82785a096dee570a6687d0b1e81c91cb
3.8 GB Preview Download
md5:9fdefa9e1117a00b9bd6fa734935fca8
3.9 GB Preview Download
md5:e0ac9e4a1998e6636fb40703f362acd5
266.2 MB Preview Download
md5:f3c1bd1e97c764235e2845352b1e5617
1.3 GB Preview Download
md5:ac5c84255e0843330140639bc4170302
10.2 GB Preview Download
md5:34c9155c1560bead27137ef3e09a07c7
2.1 GB Preview Download
md5:d5d3842aca6810b1f4167ab30720a48c
21.4 kB Download
md5:ffd1303a280d6f7132d7432f1573f65c
2.2 kB Preview Download
md5:ffcdfca9c83605ec9c7af6f913932f28
1.5 kB Preview Download
md5:4c2164ad6d10847c9b6389277ade0e89
2.4 kB Preview Download
md5:3593e5d9cb09e6da3096cbbfe4fcba62
1.8 kB Preview Download

Additional details

Funding

Parkinson's Foundation
PF-PRF-836910
Parkinson's Foundation
PF-LAUNCH-1248418
Aligning Science Across Parkinson's
ASAP-020529
National Institutes of Health
R01NS101354

Dates

Submitted
2025-04-23